

This Document can be made available
in alternative formats upon request

State of Minnesota
HOUSE OF REPRESENTATIVES

NINETY-FIRST SESSION

H. F. No. 1246

02/14/2019 Authored by Morrison, Hamilton, Freiberg, Mann, Moran and others
The bill was read for the first time and referred to the Committee on Health and Human Services Policy
02/27/2019 By motion, recalled and re-referred to the Committee on Commerce
03/04/2019 Adoption of Report: Amended and re-referred to the Committee on Health and Human Services Policy
03/11/2019 Adoption of Report: Re-referred to the Judiciary Finance and Civil Law Division
03/18/2019 Adoption of Report: Re-referred to the Committee on Ways and Means
03/11/2020 Adoption of Report: Amended and re-referred to the Judiciary Finance and Civil Law Division without further recommendation
04/28/2020 Adoption of Report: Re-referred to the Committee on Ways and Means
Pursuant to Joint Rule 2.03, re-referred to the Committee on Rules and Legislative Administration
Adoption of Report: Re-referred to the Committee on Ways and Means
Joint Rule 2.03 has been waived for any subsequent committee action on this bill

1.1 A bill for an act
1.2 relating to health; establishing the Prescription Drug Price Transparency Act;
1.3 requiring drug manufacturers to submit drug price information to the commissioner
1.4 of health; providing civil penalties; requiring a report; proposing coding for new
1.5 law in Minnesota Statutes, chapter 62J.

1.6 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.7 Section 1. **[62J.84] PRESCRIPTION DRUG PRICE TRANSPARENCY.**

1.8 Subdivision 1. **Short title.** This section may be cited as the "Prescription Drug Price
1.9 Transparency Act."

1.10 Subd. 2. **Definitions.** (a) For purposes of this section, the terms defined in this subdivision
1.11 have the meanings given.

1.12 (b) "Biosimilar" means a drug that is produced or distributed pursuant to a biologics
1.13 license application approved under United States Code, title 42, section 262(K)(3).

1.14 (c) "Brand name drug" means a drug that is produced or distributed pursuant to:

1.15 (1) an original, new drug application approved under United States Code, title 21, section
1.16 355(c), except for a generic drug as defined under Code of Federal Regulations, title 42,
1.17 section 447.502; or

1.18 (2) a biologics license application approved under United States Code, title 45, section
1.19 262(a)(c).

1.20 (d) "Commissioner" means the commissioner of health.

1.21 (e) "Generic drug" means a drug that is marketed or distributed as:

2.1 (1) an abbreviated new drug application approved under United States Code, title 21,
2.2 section 355(j);

2.3 (2) an authorized generic drug as defined under Code of Federal Regulations, title 45,
2.4 section 447.502; or

2.5 (3) a drug that entered the market the year before 1962 and was not originally marketed
2.6 under a new drug application.

2.7 (f) "Manufacturer" means a drug manufacturer licensed under section 151.252.

2.8 (g) "New prescription drug" or "new drug" means a prescription drug approved for
2.9 marketing by the United States Food and Drug Administration for which no previous
2.10 wholesale acquisition cost has been established for comparison.

2.11 (h) "Patient assistance program" means a program that a manufacturer offers to the public
2.12 in which a consumer may reduce the consumer's out-of-pocket costs for prescription drugs
2.13 by using coupons, discount cards, prepaid gift cards, manufacturer debit cards, or by other
2.14 means.

2.15 (i) "Prescription drug" or "drug" has the meaning provided in section 151.441, subdivision
2.16 8.

2.17 (j) "Price" means the wholesale acquisition cost as defined in United States Code, title
2.18 42, section 1395w-3a(c)(6)(B).

2.19 **Subd. 3. Prescription drug price increases reporting.** (a) Beginning October 1, 2021,
2.20 a drug manufacturer must submit to the commissioner the information described in paragraph
2.21 (b) for each prescription drug for which the price was \$100 or greater for a 30-day supply
2.22 or for a course of treatment lasting less than 30 days and:

2.23 (1) for brand name drugs where there is an increase of ten percent or greater in the price
2.24 over the previous 12-month period or an increase of 16 percent or greater in the price over
2.25 the previous 24-month period; and

2.26 (2) for generic drugs where there is an increase of 50 percent or greater in the price over
2.27 the previous 12-month period.

2.28 (b) For each of the drugs described in paragraph (a), the manufacturer shall submit to
2.29 the commissioner no later than 60 days after the price increase goes into effect, in the form
2.30 and manner prescribed by the commissioner, the following information, if applicable:

2.31 (1) the name and price of the drug and the net increase, expressed as a percentage;

2.32 (2) the factors that contributed to the price increase;

3.1 (3) the name of any generic version of the prescription drug available on the market;

3.2 (4) the introductory price of the prescription drug when it was approved for marketing
3.3 by the Food and Drug Administration and the net yearly increase, by calendar year, in the
3.4 price of the prescription drug during the previous five years;

3.5 (5) the direct costs incurred by the manufacturer that are associated with the prescription
3.6 drug, listed separately:

3.7 (i) to manufacture the prescription drug;

3.8 (ii) to market the prescription drug, including advertising costs; and

3.9 (iii) to distribute the prescription drug;

3.10 (6) the total sales revenue for the prescription drug during the previous 12-month period;

3.11 (7) the manufacturer's net profit attributable to the prescription drug during the previous
3.12 12-month period;

3.13 (8) the total amount of financial assistance the manufacturer has provided through patient
3.14 prescription assistance programs, if applicable;

3.15 (9) any agreement between a manufacturer and another entity contingent upon any delay
3.16 in offering to market a generic version of the prescription drug;

3.17 (10) the patent expiration date of the prescription drug if it is under patent;

3.18 (11) the name and location of the company that manufactured the drug; and

3.19 (12) if a brand name prescription drug, the ten highest prices paid for the prescription
3.20 drug during the previous calendar year in any country other than the United States.

3.21 (c) The manufacturer may submit any documentation necessary to support the information
3.22 reported under this subdivision.

3.23 Subd. 4. **New prescription drug price reporting.** (a) Beginning October 1, 2021, no
3.24 later than 60 days after a manufacturer introduces a new prescription drug for sale in the
3.25 United States that is a new brand name drug with a price that is greater than the tier threshold
3.26 established by the Centers for Medicare and Medicaid Services for specialty drugs in the
3.27 Medicare Part D program for a 30-day supply or a new generic or biosimilar drug with a
3.28 price that is greater than the tier threshold established by the Centers for Medicare and
3.29 Medicaid Services for specialty drugs in the Medicare Part D program for a 30-day supply
3.30 and is not at least 15 percent lower in price than the referenced brand name drug when the
3.31 generic or biosimilar drug is launched, the manufacturer must submit to the commissioner,

4.1 in the form and manner prescribed by the commissioner, the following information, if
4.2 applicable:

4.3 (1) the price of the prescription drug;

4.4 (2) whether the Food and Drug Administration granted the new prescription drug a
4.5 breakthrough therapy designation or a priority review;

4.6 (3) the direct costs incurred by the manufacturer that are associated with the prescription
4.7 drug, listed separately:

4.8 (i) to manufacture the prescription drug;

4.9 (ii) to market the prescription drug, including advertising costs; and

4.10 (iii) to distribute the prescription drug; and

4.11 (4) the patent expiration date of the drug if it is under patent.

4.12 (b) The manufacturer may submit documentation necessary to support the information
4.13 reported under this subdivision.

4.14 Subd. 5. **Newly acquired prescription drug price reporting.** (a) Beginning October
4.15 1, 2021, the acquiring drug manufacturer must submit to the commissioner the information
4.16 described in paragraph (b) for each newly acquired prescription drug for which the price
4.17 was \$100 or greater for a 30-day supply or for a course of treatment lasting less than 30
4.18 days and:

4.19 (1) for a newly acquired brand name drug where there is an increase of ten percent or
4.20 greater in the price over the previous 12-month period or an increase of 16 percent or greater
4.21 in the price over the previous 24-month period; and

4.22 (2) for a newly acquired generic drug where there is an increase of 50 percent or greater
4.23 in the price over the previous 12-month period.

4.24 (b) For each of the drugs described in paragraph (a), the acquiring manufacturer shall
4.25 submit to the commissioner no later than 60 days after the acquiring manufacturer begins
4.26 to sell the newly acquired drug, in the form and manner prescribed by the commissioner,
4.27 the following information, if applicable:

4.28 (1) the price of the prescription drug at the time of acquisition and in the calendar year
4.29 prior to acquisition;

4.30 (2) the name of the company from which the prescription drug was acquired, the date
4.31 acquired, and the purchase price;

5.1 (3) the year the prescription drug was introduced to market and the price of the
5.2 prescription drug at the time of introduction;

5.3 (4) the price of the prescription drug for the previous five years;

5.4 (5) any agreement between a manufacturer and another entity contingent upon any delay
5.5 in offering to market a generic version of the manufacturer's drug; and

5.6 (6) the patent expiration date of the drug if it is under patent.

5.7 (c) The manufacturer may submit any documentation necessary to support the information
5.8 reported under this subdivision.

5.9 **Subd. 6. Public posting of prescription drug price information.** (a) The commissioner
5.10 shall post on the department's website, or may contract with a private entity or consortium
5.11 that satisfies the standards of section 62U.04, subdivision 6, to post the following information:

5.12 (1) a list of the prescription drugs reported under subdivisions 3, 4, and 5, and the
5.13 manufacturers of those prescription drugs; and

5.14 (2) information reported to the commissioner under subdivisions 3, 4, and 5.

5.15 (b) The information must be published in an easy-to-read format and in a manner that
5.16 identifies the information that is disclosed on a per-drug basis and must not be aggregated
5.17 in a manner that prevents the identification of the prescription drug.

5.18 (c) The commissioner shall not post on the department's website, or a private entity
5.19 contracting with the commissioner shall not post, any information described in this section
5.20 if the information is not public data under section 13.02, subdivision 8a; is trade secret
5.21 information under section 13.37, subdivision 1, paragraph (b); or is trade secret information
5.22 pursuant to the Defend Trade Secrets Act of 2016, United States Code, title 18, section
5.23 1836, as amended. If a manufacturer believes information should be withheld from public
5.24 disclosure pursuant to this paragraph, the manufacturer must clearly and specifically identify
5.25 that information and describe the legal basis in writing when the manufacturer submits the
5.26 information under this section. If the commissioner disagrees with the manufacturer's request
5.27 to withhold information from public disclosure, the commissioner shall provide the
5.28 manufacturer written notice that the information will be publicly posted 30 days after the
5.29 date of the notice.

5.30 (d) If the commissioner withholds any information from public disclosure pursuant to
5.31 this subdivision, the commissioner shall post to the department's website a report describing
5.32 the nature of the information and the commissioner's basis for withholding the information
5.33 from disclosure.

6.1 Subd. 7. **Consultation.** (a) The commissioner may consult with a private entity or
6.2 consortium that satisfies the standards of section 62U.04, subdivision 6; the University of
6.3 Minnesota; or the commissioner of commerce, as appropriate, in issuing the form and format
6.4 of the information reported under this section in posting information pursuant to subdivision
6.5 6 and in taking any other action for the purpose of implementing this section.

6.6 (b) The commissioner may consult with representatives of the manufacturers to establish
6.7 a standard format for reporting information under this section and may use existing reporting
6.8 methodologies to establish a standard format to minimize administrative burdens to the state
6.9 and manufacturers.

6.10 Subd. 8. **Enforcement and penalties.** (a) A manufacturer may be subject to a civil
6.11 penalty, as provided in paragraph (b), for:

6.12 (1) failing to submit timely reports or notices as required by this section;

6.13 (2) failing to provide information required under this section; or

6.14 (3) providing inaccurate or incomplete information under this section.

6.15 (b) The commissioner shall adopt a schedule of civil penalties, not to exceed \$10,000
6.16 per day of violation, based on the severity of each violation.

6.17 (c) The commissioner shall impose civil penalties under this section as provided in
6.18 section 144.99, subdivision 4.

6.19 (d) The commissioner may remit or mitigate civil penalties under this section upon terms
6.20 and conditions the commissioner considers proper and consistent with public health and
6.21 safety.

6.22 (e) Civil penalties collected under this section shall be deposited in the health care access
6.23 fund.

6.24 Subd. 9. **Legislative report.** (a) No later than January 15 of each year, beginning January
6.25 15, 2022, the commissioner shall report to the chairs and ranking minority members of the
6.26 legislative committees with jurisdiction over commerce and health and human services
6.27 policy and finance on the implementation of this section, including but not limited to the
6.28 effectiveness in addressing the following goals:

6.29 (1) promoting transparency in pharmaceutical pricing for the state and other payers;

6.30 (2) enhancing the understanding on pharmaceutical spending trends; and

6.31 (3) assisting the state and other payers in the management of pharmaceutical costs.

- 7.1 (b) The report must include a summary of the information submitted to the commissioner
- 7.2 under subdivisions 3, 4, and 5.